ICCC vs. TKNO, VNRX, ABIO, AWH, OCX, CDIO, TRIB, BMRA, MYMD, and VRAX
Should you be buying ImmuCell stock or one of its competitors? The main competitors of ImmuCell include Alpha Teknova (TKNO), VolitionRx (VNRX), ARCA biopharma (ABIO), Aspira Women's Health (AWH), OncoCyte (OCX), Cardio Diagnostics (CDIO), Trinity Biotech (TRIB), Biomerica (BMRA), MyMD Pharmaceuticals (MYMD), and Virax Biolabs Group (VRAX). These companies are all part of the "diagnostic substances" industry.
ImmuCell (NASDAQ:ICCC) and Alpha Teknova (NASDAQ:TKNO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, valuation, dividends, profitability, risk, earnings, analyst recommendations, institutional ownership and community ranking.
ImmuCell has a net margin of -18.31% compared to Alpha Teknova's net margin of -97.85%. ImmuCell's return on equity of -15.21% beat Alpha Teknova's return on equity.
Alpha Teknova has a consensus target price of $15.00, indicating a potential upside of 752.27%. Given Alpha Teknova's higher probable upside, analysts plainly believe Alpha Teknova is more favorable than ImmuCell.
13.5% of ImmuCell shares are held by institutional investors. Comparatively, 13.8% of Alpha Teknova shares are held by institutional investors. 6.6% of ImmuCell shares are held by insiders. Comparatively, 15.2% of Alpha Teknova shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
In the previous week, Alpha Teknova had 1 more articles in the media than ImmuCell. MarketBeat recorded 3 mentions for Alpha Teknova and 2 mentions for ImmuCell. Alpha Teknova's average media sentiment score of 1.60 beat ImmuCell's score of 1.44 indicating that Alpha Teknova is being referred to more favorably in the news media.
ImmuCell has higher earnings, but lower revenue than Alpha Teknova. ImmuCell is trading at a lower price-to-earnings ratio than Alpha Teknova, indicating that it is currently the more affordable of the two stocks.
ImmuCell has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500. Comparatively, Alpha Teknova has a beta of 0.39, indicating that its share price is 61% less volatile than the S&P 500.
ImmuCell received 114 more outperform votes than Alpha Teknova when rated by MarketBeat users. Likewise, 73.33% of users gave ImmuCell an outperform vote while only 33.33% of users gave Alpha Teknova an outperform vote.
Summary
Alpha Teknova beats ImmuCell on 9 of the 17 factors compared between the two stocks.
Get ImmuCell News Delivered to You Automatically
Sign up to receive the latest news and ratings for ICCC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ICCC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ImmuCell Competitors List
Related Companies and Tools
